INCY News and Press, Incyte Corporation From 11/01/21

Incyte (NASDAQ:INCY) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, before market open. The consensus EPS Estimate is $0.75 (+226.1% Y/Y) and the consensus Revenue Estimate is $744.53M (+20.0% Y/Y). In August, Seeking Alpha contributor Qingshan Capital Management calle...

Investor conference call and webcast scheduled for November 13, 2021, at 6:30 p.m. ET Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer’s (SITC) 36 ...

Incyte (NASDAQ:INCY) announces that the U.S. FDA has accepted its New Drug Application (NDA) for parsaclisib for the treatment of patients with relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL). Parsaclisib is a potent, highly se...

— Priority Review granted to NDA for relapsed or refractory marginal zone lymphoma and mantle cell lymphoma — Standard Review for NDA for relapsed or refractory follicular lymphoma Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Adminis...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the u...

The technology-heavy Nasdaq Stock Market has been rallying over the past few weeks, and the demand for advanced technology solutions is expected to rise with the continuing global, digital transformation. As such, we think it could be wise to bet on fundamentally sound tech stocks Incyte (INC...

Incyte (NASDAQ:INCY) announces the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream, a topical JAK inhibitor, as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement. The validati...

- The MAA seeks approval of ruxolitinib cream for the treatment of adolescent and adult patients with non-segmental vitiligo with facial involvement Incyte (Nasdaq:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib ...

Sometimes in life, it pays to go against the tide. That's also true in the stock market. Forgotten companies -- or those whose shares have gotten hammered -- can turn out to be excellent investment opportunities. After all, there's no better time to invest in a quality stock than when it's ...

Eli Lilly (NYSE: LLY) and Incyte 's (NASDAQ: INCY) drug, Olumiant, has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to treat hospitalized COVID-19 patients with or without remdesivir. While the EUAs for Olumiant to be used as bo...